TY - JOUR
T1 - Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia
AU - Goldberg, Ronald B.
AU - Rosenson, Robert S.
AU - Hernandez-Triana, Eric
AU - Misir, Soamnauth
AU - Jones, Michael R.
N1 - Funding Information:
Dr Goldberg has received research grants from Abbott Laboratories, GlaxoSmithKline and Roche.
Funding Information:
Dr Rosenson has participated in advisory boards for Abbott Laboratories, Amgen Inc., AstraZeneca, Hoffmann-La Roche Inc., LipoScience, Inc. and sanofi-aventis and owns stock in LipoScience, Inc. Dr Rosenson’s institution has received research grants from Amgen Inc. and Hoffman-La Roche Inc.
Funding Information:
Dr Hernandez-Triana has served on scientific advisory boards for Eli Lilly and Company, Novo Nordisk, Pfizer Inc and Roche and received consulting fees and research grants from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, MSD, Novartis and sanofi-aventis. Dr Hernandez-Triana and his immediate family do not have ownership interest and/or stocks in any pharmaceutical or device company.
Funding Information:
This study was funded by Daiichi Sankyo, Inc.
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/5
Y1 - 2013/5
N2 - Background: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol(LDL-C) ≥ 100 mg/dL (≥2.6 mmol/L) and triglycerides < 500 mg/dL (<5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: ?113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly (p < 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p < 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles.
AB - Background: A randomised, double-blind, placebo-controlled study evaluated lipid- and glucose-lowering effects of colesevelam in patients with prediabetes and primary hyperlipidaemia. We report the effect of colesevelam on lipoprotein particle concentration and particle size (determined by nuclear magnetic resonance spectroscopy) in these patients. Methods: Adults with prediabetes (World Health Organization criteria), low-density lipoprotein cholesterol(LDL-C) ≥ 100 mg/dL (≥2.6 mmol/L) and triglycerides < 500 mg/dL (<5.6 mmol/L) were randomised to colesevelam 3.75 g/day or placebo for 16 weeks. The intent-to-treat population comprised 103 colesevelam and 106 placebo recipients. Results: At the end of the study, mean reduction from baseline in total LDL particle concentration was significantly greater with colesevelam versus placebo (mean treatment difference: ?113 nmol/L; p = 0.02). Increases in total very low-density lipoprotein particle concentration (VLDL-P) and high-density lipoprotein particle concentration (HDL-P) did not differ significantly between the groups; however, with colesevelam versus placebo, there were significantly (p < 0.05) greater increases in large and medium VLDL-P and large HDL-P and reductions in small VLDL-P. Mean size increases were significantly greater with colesevelam for VLDL (mean treatment difference: 5.3 nm; p < 0.0001) and HDL (0.1 nm; p = 0.002). Conclusions: Colesevelam improved the overall atherogenic lipoprotein profile in adults with prediabetes and primary hyperlipidaemia, despite potentially less favourable changes in VLDL particles.
KW - Apolipoprotein
KW - colesevelam
KW - lipoprotein particles
KW - low-density lipoprotein
KW - prediabetes
KW - primary hyperlipidaemia
UR - http://www.scopus.com/inward/record.url?scp=84876038812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876038812&partnerID=8YFLogxK
U2 - 10.1177/1479164112461657
DO - 10.1177/1479164112461657
M3 - Article
C2 - 23152373
AN - SCOPUS:84876038812
VL - 10
SP - 256
EP - 262
JO - Diabetes and Vascular Disease Research
JF - Diabetes and Vascular Disease Research
SN - 1479-1641
IS - 3
ER -